Abstract:In this study, six N-1, N-2, or N-11 derivatives of TD-34 (a cationic cyclic cell-penetrating peptide [CPP], ACSSKKSKHCG) were designed and synthesized including both linear peptides and cyclic peptides, such as DL-1 (KWSSKKSKHCG), DLCC-1 (cyclopeptide, KWSSKKSKHCG), DL-2 (KWSSKKSKHCG-NH2 ), DLCC-2 (cyclopeptide, KWSSKKSKHCG-NH2 ), DL-3 (RWSSKKSKHCG), and DLCC-3 (cyclopeptide, RWSSKKSKHCG). The cyclic peptides were synthesized by disulfide bound linkages formed by N-2 and N-10 cysteine. In vitro penetration experiment was conducted to investigate the transdermal enhancement ability of these derivatives, using triptolide (TP) as model drug. The results display that at the presence of DLCC-2, the accumulative penetration amount of TP increased 1.71-fold (P < .05) within 12 hours, displaying better transdermal enhancing ability than TD-34. Meanwhile, DL-3 and DLCC-3 slightly decreased the transdermal delivery of TP, and the presence of DL-1 and DLCC-1 shows no obvious effect. In order to clarify the factors on the transdermal ability of peptides, the solubility of TP in phosphate buffer saline (PBS) at the presence of different peptides and the mechanism of transdermal delivery of CPPs was investigated. The result shows that most of these peptides have no significant effect on the solubility of TP except DLCC-3 (the solubility of TP slightly increased). And in order to investigate transdermal absorption route of DLCC-2, polyarginine linked to rhodamine b (Rh b) derivative is used. The result proved that the transdermal route of polyarginine is via hair follicle, which may change the transdermal route of its cargo molecule (TP). Our group previously proved that polyarginine and TD-34 have similar transdermal enhancing mechanism (changing the transdermal route of their cargo molecule); it is reasonably speculated that the transdermal route of DLCC-2 is the same as polyarginine and then changes the transdermal absorption route of TP. Furthermore, such results have laid a solid foundation for further investigation of CPPs and paved a way for both designing and synthesizing of new drug delivery system for therapy molecules.

Stapling of short cell-penetrating peptides for enhanced tumor cell-and-tissue dual-penetration

Cell-penetrating peptide: a means of breaking through the physiological barriers of different tissues and organs

The role of cell‐penetrating peptides in potential anti‐cancer therapy

Cell penetrating peptides: Highlighting points in cancer therapy

Cell-Penetrating Peptides: Applications in Tumor Diagnosis and Therapeutics

Progress in tumour-targeted drug delivery based on cell-penetrating peptides

Development of Hydrophobic Cell-Penetrating Stapled Peptides as Drug Carriers

Cell-Penetrating Peptides (CPPs) as Therapeutic and Diagnostic Agents for Cancer

Penetrating peptides: Applications in drug delivery

Effect of Stapling Architecture on Physiochemical Properties and Cell Permeability of Stapled Α‐helical Peptides: A Comparative Study

Tumor microenvironment-responsive cell-penetrating peptides: Design principle and precision delivery

Advancement and application of novel cell-penetrating peptide in cancer management

[Advances in the research and application of cell penetrating peptides]

Dual-modified penetratin peptides: Enhancing nucleic acid delivery through stapling and endosomal escape domain

Cell penetrating peptides improve tumor delivery of cargos through neuropilin-1-dependent extravasation

Cell-Penetrating Peptides: A Powerful Tool for Targeted Drug Delivery

Synthesis, characterization, and evaluation of novel cell-penetrating peptides based on TD-34

A novel strategy based on a ligand-switchable nanoparticle delivery system for deep tumor penetration

New generation of cell‐penetrating peptides: Functionality and potential clinical application

Application of activatable cell-penetrating peptide in the field of tumor therapy

Discovery of endosomalytic cell-penetrating peptides based on bacterial membrane-targeting sequences